Astec LifeSciences Limited recorded an annual consolidated operating revenue of approximately ₹453.14 crore for the financial year, marking a positive recovery and a year-on-year growth rate of roughly 17.13 percent. This revenue performance is driven by its core operations in manufacturing specialty agrochemical active ingredients, triazole fungicides, and executing contract development and manufacturing organization (CDMO) projects for domestic and international client markets across multiple global regions.